Sami Mahrus

3.3k total citations · 1 hit paper
29 papers, 2.3k citations indexed

About

Sami Mahrus is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Sami Mahrus has authored 29 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 15 papers in Molecular Biology and 9 papers in Cancer Research. Recurrent topics in Sami Mahrus's work include Peptidase Inhibition and Analysis (5 papers), Advanced biosensing and bioanalysis techniques (4 papers) and Ubiquitin and proteasome pathways (4 papers). Sami Mahrus is often cited by papers focused on Peptidase Inhibition and Analysis (5 papers), Advanced biosensing and bioanalysis techniques (4 papers) and Ubiquitin and proteasome pathways (4 papers). Sami Mahrus collaborates with scholars based in United States, United Kingdom and Switzerland. Sami Mahrus's co-authors include Charles S. Craik, James A. Wells, Alma L. Burlingame, Jennifer L. Harris, Jonathan C. Trinidad, Jonathan A. Ellman, Francesco Leonetti, Bradley J. Backes, Andrej Săli and David T. Barkan and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Journal of the American Chemical Society.

In The Last Decade

Sami Mahrus

29 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b–2, study

2025 26 citations Richard Finn, Baek‐Yeol Ryoo et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sami Mahrus United States	19	1.5k	586	337	337	266	29	2.3k
Bruno Catimel Australia	26	1.5k 1.0×	488 0.8×	297 0.9×	142 0.4×	196 0.7×	73	2.3k
Simon Bergqvist United States	25	1.5k 1.0×	599 1.0×	315 0.9×	327 1.0×	70 0.3×	35	2.3k
Wouter A. van der Linden Netherlands	24	1.5k 1.0×	621 1.1×	198 0.6×	190 0.6×	138 0.5×	42	2.2k
Marko Fonovič Slovenia	24	1.5k 1.0×	600 1.0×	203 0.6×	566 1.7×	72 0.3×	49	2.7k
Robert L. Simmer United States	19	1.4k 0.9×	351 0.6×	168 0.5×	302 0.9×	282 1.1×	25	2.3k
John Sensintaffar United States	17	2.0k 1.3×	424 0.7×	480 1.4×	284 0.8×	222 0.8×	29	2.8k
Cyril Bařinka Czechia	35	2.1k 1.4×	1.3k 2.2×	220 0.7×	182 0.5×	64 0.2×	110	3.7k
Maria G. Pallavicini United States	27	1.8k 1.2×	877 1.5×	512 1.5×	549 1.6×	617 2.3×	81	3.6k
Vítor M. Faça Brazil	29	2.1k 1.4×	449 0.8×	335 1.0×	484 1.4×	74 0.3×	92	3.2k
Maria Sunnerhagen Sweden	27	1.5k 1.0×	263 0.4×	328 1.0×	152 0.5×	182 0.7×	52	2.2k

Countries citing papers authored by Sami Mahrus

Since Specialization

Citations

This map shows the geographic impact of Sami Mahrus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sami Mahrus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sami Mahrus more than expected).

Fields of papers citing papers by Sami Mahrus

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sami Mahrus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sami Mahrus. The network helps show where Sami Mahrus may publish in the future.

Co-authorship network of co-authors of Sami Mahrus

This figure shows the co-authorship network connecting the top 25 collaborators of Sami Mahrus. A scholar is included among the top collaborators of Sami Mahrus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sami Mahrus. Sami Mahrus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Finn, Richard, Baek‐Yeol Ryoo, Daneng Li, et al.. (2025). Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b–2, study. The Lancet Oncology. 26(2). 214–226. 26 indexed citations breakdown →

Cosgrove, David, Sairy Hernandez, Sarika Ogale, et al.. (2025). Atezolizumab Plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Real-World Experience From a US Community Oncology Network. Journal of Hepatocellular Carcinoma. Volume 12. 791–804. 3 indexed citations

Cosgrove, David, Sairy Hernandez, Sarika Ogale, et al.. (2024). Atezolizumab plus bevacizumab (A+B) in patients with unresectable hepatocellular carcinoma (uHCC): Real-world experience from a US community oncology network.. Journal of Clinical Oncology. 42(3_suppl). 447–447. 1 indexed citations

Ton, Thanh G.N., Navdeep Pal, Huong Trinh, et al.. (2022). Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non–Small Cell Lung Cancer Trials Using Real-World Data. Clinical Cancer Research. 28(13). 2844–2853. 13 indexed citations

Gupta, Shilpa, et al.. (2021). Overall survival of patients with metastatic castrate-resistant prostate cancer (mCRPC) who have PTEN tumor suppressor gene loss of function.. Journal of Clinical Oncology. 39(6_suppl). 58–58. 3 indexed citations

Downer, Mary K., Peter Lambert, Sami Mahrus, et al.. (2020). Abstract 29: Utility of novel clinico-genomic data to understand patient characteristics, treatments, and outcomes according to PIK3CA mutation status among hormone receptor-positive metastatic breast cancer patients. Clinical Cancer Research. 26(12_Supplement_1). 29–29. 1 indexed citations

Chau, Ian, Georg Martin Haag, Osama E. Rahma, et al.. (2018). MORPHEUS: A phase Ib/II umbrella study platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT)-based combinations in different tumour types. Annals of Oncology. 29. viii439–viii440. 14 indexed citations

Infante, Jeffrey R., Antoine Hollebecque, Sophie Postel‐Vinay, et al.. (2016). Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors. Clinical Cancer Research. 23(10). 2423–2432. 59 indexed citations

Infante, Jeffrey R., Antoine Hollebecque, Sophie Postel‐Vinay, et al.. (2015). Abstract CT139: Phase I study of GDC-0425, a checkpoint kinase 1 inhibitor, in combination with gemcitabine in patients with refractory solid tumors. Cancer Research. 75(15_Supplement). CT139–CT139. 5 indexed citations

10.

Crawford, Emily, Julia E. Seaman, Nicholas J. Agard, et al.. (2012). The DegraBase: A Database of Proteolysis in Healthy and Apoptotic Human Cells. Molecular & Cellular Proteomics. 12(3). 813–824. 119 indexed citations

11.

Gray, Daniel C., Sami Mahrus, & James A. Wells. (2010). Activation of Specific Apoptotic Caspases with an Engineered Small-Molecule-Activated Protease. Cell. 142(4). 637–646. 160 indexed citations

12.

Mahrus, Sami, Jonathan C. Trinidad, David T. Barkan, et al.. (2008). Global Sequencing of Proteolytic Cleavage Sites in Apoptosis by Specific Labeling of Protein N Termini. Cell. 134(5). 866–876. 372 indexed citations

13.

Yoshihara, Hikari A. I., Sami Mahrus, & James A. Wells. (2008). Tags for labeling protein N-termini with subtiligase for proteomics. Bioorganic & Medicinal Chemistry Letters. 18(22). 6000–6003. 41 indexed citations

14.

Mahrus, Sami & Charles S. Craik. (2005). Selective Chemical Functional Probes of Granzymes A and B Reveal Granzyme B Is a Major Effector of Natural Killer Cell-Mediated Lysis of Target Cells. Chemistry & Biology. 12(5). 567–577. 132 indexed citations

15.

Mahrus, Sami, Walter Kisiel, & Charles S. Craik. (2004). Granzyme M Is a Regulatory Protease That Inactivates Proteinase Inhibitor 9, an Endogenous Inhibitor of Granzyme B. Journal of Biological Chemistry. 279(52). 54275–54282. 79 indexed citations

16.

Bell, Jessica K., David H. Goetz, Sami Mahrus, et al.. (2003). The oligomeric structure of human granzyme A is a determinant of its extended substrate specificity. Nature Structural & Molecular Biology. 10(7). 527–534. 65 indexed citations

17.

Ziermann, Rainer, Neil Parkin, Dustin J. Maly, et al.. (2002). Altered Substrate Specificity of Drug-Resistant Human Immunodeficiency Virus Type 1 Protease. Journal of Virology. 76(3). 1359–1368. 42 indexed citations

18.

Person, Maria D., Kathlynn C. Brown, Sami Mahrus, Charles S. Craik, & Alma L. Burlingame. (2001). Novel inter‐protein cross‐link identified in the GGH‐ecotin D137Y dimer. Protein Science. 10(8). 1549–1562. 20 indexed citations

19.

Sambrano, Gilberto R., et al.. (2000). Cathepsin G Activates Protease-activated Receptor-4 in Human Platelets. Journal of Biological Chemistry. 275(10). 6819–6823. 276 indexed citations

20.

Harris, Jennifer L., Bradley J. Backes, Francesco Leonetti, et al.. (2000). Rapid and general profiling of protease specificity by using combinatorial fluorogenic substrate libraries. Proceedings of the National Academy of Sciences. 97(14). 7754–7759. 450 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact